TD Cowen analyst Brendan Smith has maintained their bullish stance on ABCL stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brendan Smith has given his Buy rating due to a combination of factors that highlight AbCellera Biologics’ promising future in the biotech sector. The company has recently achieved a significant milestone with the initiation of dosing for its clinical asset, ABCL-575, targeting moderate-to-severe vasomotor symptoms associated with menopause. This market, which affects approximately 30% of women, represents a substantial opportunity estimated at over $2 billion. The management anticipates that ABCL-575 will stand out from existing treatments due to its improved safety profile and more convenient dosing schedule.
Furthermore, AbCellera’s ongoing development of ABCL-575 for atopic dermatitis and the anticipated filing of an IND for ABCL-688 targeting an undisclosed autoimmune indication underscore the company’s expanding pipeline. These developments, coupled with the expected data readouts in mid-2026, are set to provide crucial insights into the efficacy and positioning of these assets. Smith believes that AbCellera’s strategic focus on building out its clinical programs will drive significant stock catalysts over the next couple of years, justifying the Buy rating.
In another report released on July 28, Piper Sandler also maintained a Buy rating on the stock with a $17.00 price target.